-
Lynk Pharmaceuticals Doses First Patient in Phase III Trial for Atopic Dermatitis Treatment
•
Lynk Pharmaceuticals Co., Ltd, based in China, has announced the dosing of the first patient in a Phase III clinical study for its highly selective JAK1 inhibitor, LNK01001, aimed at treating atopic dermatitis (AD). This randomized, double-blind, placebo-controlled trial is designed to evaluate the efficacy and safety of LNK01001 in…
-
Lynk Pharmaceuticals Initiates Phase III Clinical Trial for Rheumatoid Arthritis Drug in China
•
China-based Lynk Pharmaceuticals Co., Ltd has announced that the first patient has been dosed in a Phase III clinical study for its drug candidate LNK01001, which is being developed to treat rheumatoid arthritis (RA). The trial is supported by Lynk’s commercialization partner, Simcere Pharmaceutical Group (HKG: 2096), and is being…
-
Lynk Pharmaceuticals Secures Series C2 Financing to Advance pipeline
•
Lynk Pharmaceuticals Co., Ltd, a China-based pharmaceutical company, has announced the successful completion of its Series C2 financing round. The round saw participation from the Shaoxing Binhai New Area Biomedical Industry Equity Investment Fund, managed by China Grand Prosperity Investment, Haibang Venture, and Howbuy Primary Fund, with existing shareholders New…
-
Lynk Pharmaceuticals’ LNK01001 Shows Positive Results in Ankylosing Spondylitis Phase II Study
•
China-based Lynk Pharmaceuticals Co., Ltd has announced positive topline results from the Phase II clinical study of its pipeline candidate, LNK01001, in the treatment of ankylosing spondylitis (AS). The randomized, double-blind, placebo-controlled, multi-center study involved 177 AS patients who had previously experienced insufficient efficacy or intolerance to non-steroidal anti-inflammatory drugs…
-
Lynk Pharmaceuticals’ LNK01001 Shows Positive Results in Atopic Dermatitis Phase II Study
•
China-based Lynk Pharmaceuticals Co., Ltd has announced that its Phase II clinical study for LNK01001 in atopic dermatitis (AD) has yielded positive major results. The study, a randomized, double-blinded, placebo-controlled, multi-center trial, enrolled 150 patients and included high-dose and low-dose groups of LNK01001 alongside a placebo group. Study Design and…
-
Lynk Pharmaceuticals Secures RMB 200 Million in Series C1 Financing Round
•
China-based Lynk Pharmaceuticals Co., Ltd has successfully raised RMB 200 million (USD 28.3 million) through a Series C1 financing round. The investment was led by China Grand Prosperity Investment, with participation from Tailong VC and LIANDO. The proceeds from this funding round will be utilized to accelerate the clinical development…
-
Lynk Pharmaceuticals’ LNK01001 Demonstrates Efficacy in Phase II Rheumatoid Arthritis Study
•
China-based Lynk Pharmaceuticals Co., Ltd announced positive results from the Phase II clinical study of its drug candidate LNK01001 in treating rheumatoid arthritis (RA). The study demonstrated a statistically significant efficacy difference in terms of primary and key secondary endpoints, along with a favorable safety and tolerability profile. LNK01001: A…
-
EQRx Inc. Abandons Plans for Low-Cost Drugs, Terminates Development of Three China-Sourced Products
•
US-based biotech EQRx Inc., (Nasdaq: EQRX) has disclosed in its Q4 2022 financial report a significant shift in strategy. The company, which aimed to disrupt high drug prices in the US market with cheaply sourced innovative drugs, has decided to abandon these plans. Consequently, EQRx will terminate the development of…
-
Lynk Pharmaceuticals Concludes Phase I Study for JAK Inhibitor LNK01003 with Positive Results
•
China-based Lynk Pharmaceuticals (Hangzhou) Co., Ltd has announced the successful conclusion of a Phase I clinical study for its Category 1 innovative drug candidate, LNK01003. The trial, which assessed the molecule in healthy volunteers, demonstrated a good safety profile, tolerability, and pharmacokinetics. Design and Outcomes of the Phase I StudyThe…
-
Lynk Pharmaceuticals Doses First Patient in Phase II Study for LNK01003
•
China-based Lynk Pharmaceuticals (Hangzhou) Co., Ltd announced first patient dosing in a Phase II clinical study assessing the efficacy and safety of its Category 1 innovative drug candidate LNK01003 in active ulcerative colitis (UC). Ulcerative Colitis and LNK01003Ulcerative colitis is one of the two main forms of inflammatory bowel disease…
-
Lynk Pharma Gets NMPA Green Light for LNK01004 Atopic Dermatitis Study
•
Hangzhou-based Lynk Pharmaceuticals Co., Ltd announced it has received approval from the National Medical Products Administration (NMPA) to conduct a clinical study of its drug LNK01004 for atopic dermatitis (AD). The drug was previously approved for a clinical trial in mild to moderate plaque psoriasis, with the first patient dosed…
